Vasoconstriction compositions and methods of use
AssigneeEye Therapies LLC
InventorGerald HORN
Life of this patent
Estimating the term…
Abstract
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Claims54
-13. (canceled)
A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising brimonidine as the sole active ingredient at a concentration less than 0.07%, wherein the ophthalmic formulation is administered no more than 4 time a day.
A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising brimonidine as the sole active ingredient at a concentration less than 0.07%, wherein said administration does not result in ocular ischemia.
A method of reducing ocular redness in a subject in need thereof comprising administering to the ocular surface a single drop of an ophthalmic formulation comprising as the sole active ingredient at a concentration less than 0.07% wherein said administration is not within 24 hrs. prior to or after the subject has had an ocular surgery.
A formulation comprising 0.025% brimonidine as the sole active ingredient, glycerin, potassium chloride, calcium chloride dehydrate, benzalkonium chloride, water wherein said formulation is suitable for administration to the ocular surface.
A formulation comprising 0.09% or less brimonidine as the sole active ingredient and one or more of a surfactant, electrolyte, or preservative.
Dependencies are inferred from the claim text.